EU warns against 2nd AstraZeneca shot for people with blood clots; Spain lifts suspension

EU advises against second AstraZeneca shot for people with blood clots The second shot of the COVID-19 vaccine developed by AstraZeneca and the University of Oxford must not be given to anyone who has had blood clots with low blood platelets after receiving the first, Europe's medicines regulator said on Friday. Pushkala Aripaka U.S.

(Reuters) -The second shot of the COVID-19 vaccine developed by AstraZeneca and the University of Oxford must not be given to anyone who has had blood clots with low blood platelets after receiving the first, Europe’s medicines regulator said on Friday.

The advice for healthcare professionals was provided by the European Medicines Agency (EMA) as part of an ongoing review into rare, but severe blood clots possibly linked to inoculation after the shot and also to Johnson & Johnson’s coronavirus vaccine.

The EMA has been looking into such clots in the abdomen and brain since March and has recommended that both vaccine labels carry a warning on the clotting issues while maintaining that the overall benefits outweighed any risks.

Both the AstraZeneca and J&J vaccine use different versions of a cold virus to deliver instructions for making coronavirus proteins into cells to produce an immune response.

"While blood clots with low blood platelets following vaccination are very rare, EMA continues to advise people to be aware of symptoms ... so they can receive prompt specialised medical treatment if needed," the EMA said here on Friday.

The watchdog said people should be on guard for any signs of any blood clots or low platelets within three weeks of receiving the first shot of AstraZeneca’s vaccine, Vaxzevria, and that the latest recommendations will be added to the vaccine’s product information. ...

ALSO SEE: Spain to lift suspension of AstraZeneca vaccine for second dose in people under 60